SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement

Monoclonal antibodies (mAbs) are emerging as safe and effective therapeutics against SARS-CoV-2. However, variant strains of SARS-CoV-2 have evolved, with early studies showing that some mAbs may not sustain their efficacy in the face of escape mutants. Also, from the onset of the COVID-19 pandemic,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying-Ting, Allen, Robert D., Kim, Kenneth, Shafee, Norazizah, Gonzalez, Andrew J., Nguyen, Michael N., Valentine, Kristen M., Cao, Xia, Lu, Lucy, Pai, Chin-I, Johnson, Sachi, Kerwin, Lisa, Zhou, Heyue, Zhang, Yanliang, Shresta, Sujan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498781/
https://www.ncbi.nlm.nih.gov/pubmed/34634289
http://dx.doi.org/10.1016/j.antiviral.2021.105185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8498781/
https://www.ncbi.nlm.nih.gov/pubmed/34634289
http://dx.doi.org/10.1016/j.antiviral.2021.105185

Ejemplares similares